Cantor Fitzgerald Analysts Give Celgene (CELG) a $112.00 Price Target
“The Wall Street Journal (WSJ) has reported that CELG is in talks to buy JUNO (NC), or rather the 90% of the company that CELG does not already own.”,” the firm’s analyst wrote.
Other equities research analysts have also issued research reports about the company. UBS Group lowered Celgene from a strong-buy rating to a market perform rating and set a $160.00 target price for the company. in a research note on Thursday, October 26th. BMO Capital Markets lowered their target price on Celgene from $163.00 to $148.00 and set an outperform rating for the company in a research note on Friday, October 27th. Robert W. Baird lowered Celgene from an outperform rating to a neutral rating and lowered their target price for the company from $162.00 to $136.00 in a research note on Friday, October 20th. BTIG Research reiterated a hold rating on shares of Celgene in a research note on Sunday, October 22nd. Finally, Vetr upgraded Celgene from a buy rating to a strong-buy rating and set a $144.39 target price for the company in a research note on Monday, October 23rd. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. Celgene presently has an average rating of Buy and a consensus target price of $129.98.
Celgene (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The company had revenue of $3.29 billion during the quarter, compared to analyst estimates of $3.42 billion. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The firm’s revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the firm posted $1.58 earnings per share. research analysts predict that Celgene will post 6.7 EPS for the current year.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Winslow Evans & Crocker Inc. increased its position in Celgene by 25.6% in the 4th quarter. Winslow Evans & Crocker Inc. now owns 11,780 shares of the biopharmaceutical company’s stock valued at $1,229,000 after acquiring an additional 2,404 shares during the period. Ingalls & Snyder LLC increased its position in Celgene by 112.0% in the 4th quarter. Ingalls & Snyder LLC now owns 57,231 shares of the biopharmaceutical company’s stock valued at $5,973,000 after acquiring an additional 30,230 shares during the period. TRUE Private Wealth Advisors acquired a new stake in Celgene in the 4th quarter valued at approximately $241,000. State of Alaska Department of Revenue increased its position in Celgene by 1,777.2% in the 4th quarter. State of Alaska Department of Revenue now owns 80,437 shares of the biopharmaceutical company’s stock valued at $8,393,000 after acquiring an additional 76,152 shares during the period. Finally, Syntal Capital Partners LLC acquired a new stake in Celgene in the 4th quarter valued at approximately $407,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.